Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

I. Medizinische Klinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Publikationen
Ergebnisse pro Seite:  10

Molokanova, O.; Schoenig, K.; Weng, S. -Y. et al.

GENERATION AND CHARACTERIZATION OF A MYOFIBROBLASTS SPECIFIC CONDITIONAL Col3a1a-CreERT2 MOUSE MODEL TO STUDY LIVER FIBROSIS

JOURNAL OF HEPATOLOGY. Bd. 62. 2015 S. S470-S470


Relle, Manfred; Weinmann-Menke, Julia; Scorletti, Eva et al.

Genetics and novel aspects of therapies in systemic lupus erythematosus

AUTOIMMUNITY REVIEWS. Bd. 14. H. 11. 2015 S. 1005-1018


Tomer, Yaron; Dolan, Lawrence M.; Kahaly, George et al.

Genome wide identification of new genes and pathways in patients with both autoimmune thyroiditis and type 1 diabetes

JOURNAL OF AUTOIMMUNITY. Bd. 60. 2015 S. 32-39



Steven, S.; Kopp, M.; Mikhed, Y. et al.

Glucagon-like peptide 1 (GLP1) improves disseminated intravasal coagulation (DIC) and vascular function in LPS-induced endotoxemia

EUROPEAN HEART JOURNAL. Bd. 36. 2015 S. 437-438


Hiromatsu, Yuji; Wall, Jack R.; Kahaly, George J. et al.

Graves' Orbitopathy

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY. 2015


Gehrke, Nadine; Woerns, Marcus A.; Alt, Yvonne et al.

Hepatocyte-specific overexpression of B cell leukemia-3 in mice suppresses chemically-induced hepatocarcinogenesis

HEPATOLOGY. Bd. 62. 2015 S. 1158A-1158A


Baek, Jea-Hyun; Zeng, Rui; Weinmann-Menke, Julia et al.

IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease

JOURNAL OF CLINICAL INVESTIGATION. Bd. 125. H. 8. 2015 S. 3198-3214


Weinmann-Menke, J.; Sollinger, D.; Schamberger, B. et al.

IL-34 MEDIATES ACUTE KIDNEY INJURY WORSENING SUBSEQUENT CHRONIC KIDNEY DISEASE

TRANSPLANT INTERNATIONAL. Bd. 28. 2015 S. 27-27


Modest, Dominik P.; Stintzing, Sebastian; von Weikersthal, Ludwig Fischer et al.

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer

JOURNAL OF CLINICAL ONCOLOGY. Bd. 33. H. 32. 2015 S. 3718-+